EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Juvenescence told Longevity.Technology it has delayed its planned IPO from this year to the second half of 2020. The company now plans to raise a series C round before listing on a U.S. stock exchange. Article

> The FDA accepted DBV Technologies’ application for approval of Viaskin Peanut. The acceptance comes almost 10 months after DBV withdrew its original filing. Release 

> Bavarian Nordic began a phase 1 trial of a vaccine candidate against the equine encephalitis virus. Topline data from the 45-subject study are due next year. Statement 

> The FDA granted fast-track designation to Mereo BioPharma’s navicixizumab in ovarian cancer. The drug is in phase 1b. Release 

> Galderma said a phase 2 trial “successfully demonstrated the safety and efficacy” of its liquid botulinum toxin type A formulation. A phase 3 trial is due to start soon. Statement 

> Motif Bio revealed it will take “several years” and “tens of millions of dollars” to address the FDA’s request for additional data on its antibiotic iclaprim. Motif wants to find a partner for the trial. Release 

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.